702 reports of this reaction
1.3% of all TICAGRELOR reports
#19 most reported adverse reaction
ACUTE MYOCARDIAL INFARCTION is the #19 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 702 FDA adverse event reports linking TICAGRELOR to ACUTE MYOCARDIAL INFARCTION. This represents approximately 1.3% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience acute myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE MYOCARDIAL INFARCTION is a less commonly reported adverse event for TICAGRELOR, but still significant enough to appear in the safety profile.
In addition to acute myocardial infarction, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to acute myocardial infarction in FDA adverse event reports:
ACUTE MYOCARDIAL INFARCTION has been reported as an adverse event in 702 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE MYOCARDIAL INFARCTION accounts for approximately 1.3% of all adverse event reports for TICAGRELOR, making it a notable side effect.
If you experience acute myocardial infarction while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.